Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Krefting Research Centre, Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, University of Gothenburg, Göteborg, Sweden.
Front Immunol. 2018 Jul 27;9:1677. doi: 10.3389/fimmu.2018.01677. eCollection 2018.
Smoking is a risk factor for developing rheumatoid arthritis (RA), but the mechanism remains uncertain. We previously demonstrated that smoking lowers the T cell activation threshold by limiting programmed death protein 1 (PD-1) expression.
To investigate how smoking influence the levels of soluble PD-1 ligand (sPD-L1).
Serum levels of sPD-L1 were measured in 246 RA patients and in 168 healthy subjects. The analysis was done with respect to inflammation, smoking, treatments, and autoantibody status. The effect of therapeutic TNF-inhibiting antibodies (TNFi) on sPD-L1 was studied in 16 RA patients at their first infliximab infusion. The expression of Fcγ-receptor (FcγR) subclass IIB and IIIA was analyzed with quantitative polymerase chain reaction in peripheral blood mononuclear cells (PBMCs) from 12 RA patients and 15 healthy controls, and in healthy PBMC exposed to IgG containing antibodies to cyclic citrullinated peptides (aCCP).
The negative association between smoking and sPD-L1 in RA patients was established by multiple logistic regression (OR = 0.52, = 0.038). Other covariates in the regression model were serum levels of IL-1β representing inflammation (OR = 1.6, = 0.0076) and aCCP positivity (OR = 1.9, = 0.047). First infliximab infusion repressed sPD-L1 ( = 0.023) in patients, and low levels of sPD-L1 were found in patients with early RA treated with TNFi ( = 0.018). Treatment with TNFi was associated with higher sPD-L1 in patients with long disease duration ( = 0.041) and restored levels in smokers. exposure to aCCP+ IgG suppressed sPD-L1 ( = 0.036), but aCCP+ patients with long disease duration had higher sPD-L1 ( = 0.016). High ratio of the inhibitory FcγR subclass IIB over the stimulatory IIIA resulted in low sPD-L1 release ( = 0.029). Smoking was associated with a higher FcγR IIB/IIIA ratio ( = 0.00062) and lower levels of sPD-L1 ( = 0.013).
In RA, serum sPD-L1 was related to systemic inflammation and aCCP positivity. Smoking altered the expression of FcγRs and limited sPD-L1 in RA patients, permitting inappropriate T cell responses. Differential regulation of sPD-L1 during the early and late RA may indicate transposition from acute to chronic inflammation.
吸烟是类风湿关节炎(RA)发病的一个风险因素,但具体机制尚不清楚。我们之前的研究表明,吸烟通过限制程序性死亡蛋白 1(PD-1)的表达来降低 T 细胞的激活阈值。
研究吸烟如何影响可溶性 PD-1 配体(sPD-L1)的水平。
检测了 246 例 RA 患者和 168 例健康对照者的血清 sPD-L1 水平。分析了炎症、吸烟、治疗和自身抗体状态等因素与 sPD-L1 的关系。16 例 RA 患者在首次接受英夫利昔单抗输注时,研究了治疗性 TNF 抑制剂(TNFi)对 sPD-L1 的影响。通过定量聚合酶链反应分析了 12 例 RA 患者和 15 例健康对照者外周血单个核细胞(PBMC)中 Fcγ 受体(FcγR)亚类 IIB 和 IIIA 的表达,并在健康 PBMC 中分析了含有针对环瓜氨酸肽(aCCP)的 IgG 抗体的表达。
通过多元逻辑回归证实了 RA 患者中吸烟与 sPD-L1 之间的负相关关系(OR=0.52,P=0.038)。回归模型中的其他协变量为血清 IL-1β 水平(代表炎症,OR=1.6,P=0.0076)和 aCCP 阳性(OR=1.9,P=0.047)。首剂英夫利昔单抗输注可抑制患者的 sPD-L1(P=0.023),且早期 RA 患者接受 TNFi 治疗后 sPD-L1 水平较低(P=0.018)。TNFi 治疗与疾病病程较长的患者 sPD-L1 水平较高(P=0.041)有关,并恢复了吸烟者的 sPD-L1 水平。aCCP+IgG 可抑制 sPD-L1(P=0.036)的释放,但病程较长的 aCCP+患者 sPD-L1 水平较高(P=0.016)。抑制性 FcγR 亚类 IIB 与刺激性 FcγR IIIA 的比值升高会导致 sPD-L1 释放减少(P=0.029)。吸烟与较高的 FcγR IIB/IIIa 比值(P=0.00062)和较低的 sPD-L1 水平(P=0.013)相关。
在 RA 中,血清 sPD-L1 与系统性炎症和 aCCP 阳性有关。吸烟改变了 RA 患者 FcγR 的表达,限制了 sPD-L1 的释放,从而导致 T 细胞反应异常。RA 早期和晚期 sPD-L1 的差异调节可能表明炎症从急性向慢性的转变。